Clinical Trial Search

Phase 2 N=9 A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease

Fabry Disease

Primary: Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) — 0; 0; 0 Participants

Amicus Therapeutics Results Sep 2018 11.1% serious AE View details

Phase 2 N=9 A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

Fabry Disease

Primary: Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) — 2 Participants

Amicus Therapeutics Results Sep 2018 0.0% serious AE View details

Phase 4 N=9 To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD

AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)

Primary: Proportion of Patients With no Fluid on OCT at Week 24

Vitreous -Retina- Macula Consultants of New York Results Sep 2018 0.0% serious AE View details

Phase 2 N=123 A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma

Melanoma

Primary: One-year Overall Survival Rate (OSR) Estimated by Complete Case Method — 83.08; 83.33; 100 Percentage of Participants

GlaxoSmithKline Results Sep 2018 15.5% serious AE View details

N/A N=3 Safety and Effectiveness of OCL 503 in the Treatment of Women With Leiomyomata

Leiomyomata

Primary: Number of Participants With Serious Adverse Events — 0; 0 Participants

IMBiotechnologies Ltd. Results Sep 2018 0.0% serious AE View details

Phase 2 N=41 Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

End Stage Renal Disease

Primary: Number of Patients That Underwent Transplantation — 32 Participants

Stanley Jordan, MD Results Sep 2018 35.9% serious AE View details

Phase 3 N=815 A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Endometriosis

Primary: Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea (DYS) — 22.7; 43.4; 72.4 percentage of participants — p=< 0.001

AbbVie Results Sep 2018 3.6% serious AE View details

Phase 2 N=155 An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis

Endometriosis, Pain

Primary: Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain at Week 12 — -0.88; -1.19; -1.25 units on a scale — p=0.2311

AbbVie Results Sep 2018 0.5% serious AE View details

Phase 1 N=8 A Positron Emission Tomography (PET) Imaging Study to Investigate the Biodistribution and Clearance of an Albumin Binding Domain Antibody (AlbudAb) GSK3128349 in Healthy Male Subjects

Drug-Related Side Effects and Adverse Reactions

Primary: Mean Standardized Uptake Values (SUVs) Derived From Positron Emission Tomography-Computer Tomography (PET-CT) Data — 0.515; 0.566; 0.607; 0.623 Ratio

GlaxoSmithKline Results Sep 2018 0.0% serious AE View details

Phase 2 N=5 A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

Fabry Disease

Primary: Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) — 0 Participants

Amicus Therapeutics Results Sep 2018 0.0% serious AE View details

Phase 3 N=495 Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain

Endometriosis

Primary: Percentage of Participants With a Response for Dysmenorrhea at Month 6 Based on Daily Assessment — 37.0; 57.1; 50.8; 75.9 percentage of participants

AbbVie Results Sep 2018 5.5% serious AE View details

N/A N=1,602 Long-term Observation PMS for Afatinib

Carcinoma, Non-Small-Cell Lung

Primary: Incidence of Adverse Drug Reactions (ADRs) — 95.19 Percentage of Participants

Boehringer Ingelheim Results Sep 2018 70.5% serious AE View details

N/A N=60 Physical Activity for Older Adults Chronic Low Back Pain

Low Back Pain

Primary: Timed Get-Up-And Go — -1.84; -2.15; 1.11 seconds — p=0.08

VA Office of Research and Development Results Sep 2018 3.3% serious AE View details

Phase 3 N=879 Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Primary: Change in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment — -0.94; -0.12; -0.91; -0.33 Percentage (%) — p=<0.0001

Boehringer Ingelheim Results Sep 2018 2.9% serious AE View details

Phase 1 N=48 Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects

Hereditary Angioedema (HAE)

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs ) Including Serious Adverse Events (SAEs) — 8; 4; 3; 8 Participants

Shire Results Sep 2018 0.0% serious AE View details